Navigation Links
New research project aims to improve cancer therapies using type I interferons

The immune system plays a decisive role in the fight against tumor cells. However, when tumor cells themselves prevent activation of the immune system, the immune system fails to destroy cancer cells. The cancer drug interferon-α could probably neutralize this blockade. This cytokine is being used successfully to treat various forms of cancer. However, some patients experience undesirable autoimmune reactions on administration of the drug. The German Cancer Aid (Deutsche Krebshilfe e.V.) is donating EUR 180,000 to fund a research project at the University Medical Center of Johannes Gutenberg University Mainz that is to identify mechanisms underlying the effects of the cancer drug interferon-α (IFN-α) when it comes to fighting cancer cells by means of the blockade of so-called immunological tolerance processes. In addition, the researchers want to discover novel approaches to increase the efficacy of type I interferons in the treatment of cancer.

Interferon-α can trigger autoimmune reactions in patients, i.e., pathological reactions of the immune system. Interferon-α has been seen to date as an active substance that boosts the immune system and fights tumor cells directly. It is used, for example, in the therapy of malignant melanomas, certain forms of leukemia and cutaneous T-cell lymphomas. "The immune system is usually able to effectively destroy cancer cells. At the same time, however, there are also so-called tumor-associated tolerance processes that protect the tumor cells from being destroyed by the immune system. Autoimmune reactions, which are known side effects of therapies with IFN-α, may indicate that this anti-tumor treatment blocks tolerance mechanisms and thus improves the immune system's natural ability for tumor rejection," explained Professor Dr. Kerstin Steinbrink, senior physician at the Department of Dermatology of the Mainz University Medical Center, which is supervising the research project "Analysis of the Effect of Type I Interferons on Immunological Tolerance Processes" funded by the German Cancer Aid. The purpose of this project is to analyze the effects of IFN-α and other type I interferons on various immune cells that exhibit tolerogenic potential in vitro and also in melanoma patients.

The knowledge gained through this project should contribute to the development of improved therapy strategies for overcoming tolerance mechanisms associated with tumors. An additional objective is to enhance the efficacy of therapy with type I interferons. Steinbrink's research team is looking to reduce potential side effects as much as possible.

"This research project is taking a patient-oriented approach. The research team led by Professor Dr. Kerstin Steinbrink will profit from its expertise in the area of immunological tolerance that it has gained over several years," said Professor Dr. Ulrich Frstermann, Chief Scientific Officer of the Mainz University Medical Center.


Contact: Dr. Reneé Dillinger-Reiter
Johannes Gutenberg Universitaet Mainz

Related medicine news :

1. Should kids sit less or move more? CHEO Research answers
2. The Melanoma Research Alliance Foundation supports CNIO research
3. Deficiency in p53 anti-tumor protein delays DNA repair after radiation, Moffitt researchers say
4. Latest research shows 2 items are key to decrease symptoms and prolong survival for LMC patients
5. Wayne State researchers seek calcium channels to target cancer tumors
6. Medical Device Market: Peru & Philippines New Market Research Report Available At
7. Toothpaste and Toothbrush Manufacturing in China Industry Research Report – Now Available from IBISWorld
8. Medical Robotic Systems Market - New Market Research Report Published by Transparency Market Research
9. Sickle cell project named among Top 10 Clinical Research Achievements for 2012
10. Feinstein Institute Researcher provides insight into osteoarthritis
11. Cleveland Clinic Childrens Hospital research suggests transmission of respiratory viruses in utero
Post Your Comments:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology: